

OMB APPROVAL
OMB Number: 3235-0416
Expires: April 30, 2010
Estimated average burden hours per response 182

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE
SECURITIES ACT OF 1934

For the quarterly period ended November 30, 2007

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES ACT OF 1934

For the transition period from _____ to _____

Commission file number: 0-49685

Bi-Optic Ventures Inc.

(Exact name of small business issuer as specified in its charter)

British Columbia, Canada
(Jurisdiction of Incorporation/Organization)

N/A
(IRS Tax ID No.)

1030 West Georgia Street #1518, Vancouver, British Columbia, Canada V6E 2Y3
(Address of principal executive offices)

Issuer's Telephone Number: 604-689-2646

Check whether the issuer (1) filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for
such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days.
Yes xxx No ____

Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act). Yes xxx No ____

State the number of shares outstanding of each of the issuer's classes of
common stock as of 12/31/2007: 10,012,235 Common Shares w/o par value

Transitional Small Business Disclosure Format (Check one): Yes ____ No xxx

SEC 2334 (06-07) Persons who are to respond to the collection of information contained in this form are
not required to respond unless the form displays a currently valid OMB control number.

PART I
FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

BI-OPTIC VENTURES INC.
FINANCIAL STATEMENTS
NINE MONTHS ENDED
NOVEMBER 30, 2007 AND 2006

Bi-Optic Ventures Inc.
(A Development Stage Company)
Balance Sheets
(expressed in Canadian dollars)

	November 30, 2007 \$ (unaudited)	February 28, 2007 \$
Assets		
Current Assets		
Cash	14,610	-
Amounts receivable	2,515	6,642
Advances to Pacific Bio-Pharmaceuticals, Inc. (Note 4)	29,065	-
Advances to related party (Note 4)	3,582	-
Prepaid expenses	20,421	5,921
Total Current Assets	70,193	12,563
Property and Equipment (Note 3)	15,157	14,138
Deferred Acquisition Costs (Note 5)	5,456	-
Total Assets	90,806	26,701
Liabilities and Stockholders' Deficit		
Current Liabilities		
Bank indebtedness	-	830
Accounts payable	40,021	49,376
Accrued liabilities	-	1,600
Interest payable (Note 6)	7,280	-
Loans payable (Note 6)	200,007	-
Due to related parties (Note 4)	126,727	21,186
Total Liabilities	374,035	72,992
Stockholders' Deficit		
Common Stock: Unlimited common shares authorized without par value; 10,012,235 shares issued and outstanding	3,768,180	3,768,180
Deficit Accumulated During the Development Stage	(4,051,409)	(3,814,471)
Total Stockholders' Deficit	(283,229)	(46,291)
Total Liabilities and Stockholders' Deficit	90,806	26,701

(The accompanying notes are an integral part of the financial statements)

Bi-Optic Ventures Inc.
(A Development Stage Company)
Statements of Operations
(expressed in Canadian dollars)
(unaudited)

	Accumulated from May 31, 1984 (Date of Inception) to November 30, 2007 \$	Three months ended November 30, 2007 2006 \$ \$		Nine months ended November 30, 2007 2006 \$ \$	
Revenue	—	—	—	—	—
Expenses					
Acquisition costs written off	347,815	—	—	—	—
Amortization	13,117	922	1,072	3,434	1,645
Bad debts	20,658	—	—	—	—
Consulting and management fees (Note 4(a))	611,189	34,028	26,810	73,135	83,076
Investor and public relations	88,155	1,287	1,200	4,516	3,900
Office, rent and telephone (Note 4(b))	364,323	20,466	13,597	52,285	37,617
Professional fees (Note 4(c))	535,740	45,961	35,399	74,426	74,594
Transfer agent and regulatory fees	100,486	1,884	2,978	9,507	13,085
Travel and promotion	298,717	1,900	17,173	19,635	61,449
Total Expenses	2,380,200	106,448	98,229	236,938	275,366
Loss from Operations	(2,380,200)	(106,448)	(98,229)	(236,938)	(275,366)
Other Income					
Write-off of accounts payable	49,341	—	—	—	—
Interest and other income	13,729	—	—	—	—
Total Other Income	63,070	—	—	—	—
Net Loss Before Discontinued Operations	(2,317,130)	(106,448)	(98,229)	(236,938)	(275,366)
Loss from Discontinued Operations	(1,734,279)	—	—	—	—
Net Loss for the Period	(4,051,409)	(106,448)	(98,229)	(236,938)	(275,366)
Net Loss Per Share – Basic and Diluted		(0.01)	(0.01)	(0.02)	(0.03)
Weighted Average Shares Outstanding		10,012,200	9,890,000	10,012,200	9,190,000

(The accompanying notes are an integral part of the financial statements)

Bi-Optic Ventures Inc.
(A Development Stage Company)
Statements of Cash Flows
(expressed in Canadian dollars)
(unaudited)

	Three months ended November 30,		Nine months ended November 30,	
	2007	2006	2007	2006
	\$	\$	\$	\$
Cash Flows To Operating Activities				
Net loss for the period	(106,448)	(98,229)	(236,938)	(275,366)
Adjustment to reconcile net loss to net cash used in operating activities				
Amortization	922	1,072	3,434	1,645
Changes in operating assets and liabilities				
Amounts receivable	1,178	(4,533)	4,127	(5,758)
Advances to related party	(21,921)		(32,647)	
Prepaid expenses	28,599	732	(14,500)	6,534
Accounts payable and accrued liabilities	5,951	(4,625)	(10,956)	12,278
Interest payable	5,955	–	7,280	–
Due to related parties	(28,290)	(24,187)	105,542	803
Net Cash Used In Operating Activities	(114,054)	(129,770)	(174,658)	(259,864)
Investing Activities				
Deferred acquisition costs	–	–	(5,456)	–
Acquisition of property and equipment	–	(12,527)	(4,453)	(12,527)
Net Cash Used in Investing Activities	–	(12,527)	(9,909)	(12,527)
Financing Activities				
Loans	129,598	–	200,007	–
Issuance of common shares, net of costs	–	222,000	–	275,700
Net Cash Provided By Financing Activities	129,598	222,000	200,007	275,700
Increase in Cash	15,544	79,703	15,440	3,309
Cash - Beginning of Period	(934)	(438)	(830)	75,956
Cash - End of Period	14,610	79,265	14,610	79,265
Supplemental Disclosures				
Interest paid	–	–	–	–
Income taxes paid	–	–	–	–

(The accompanying notes are an integral part of the financial statements)

Bi-Optic Ventures Inc.
(A Development Stage Company)
Notes to the Financial Statements
(expressed in Canadian dollars)
(unaudited)

1. Nature of Operations

Bi-Optic Ventures Inc. (the "Company") was incorporated in the Province of British Columbia, Canada on May 31, 1984. The Company filed a 10-SB Registration Statement with the U.S. Securities Exchange Commission in March 2003. On March 22, 2007, the Company entered into an agreement to acquire Pacific Bio-Pharmaceuticals, Inc. ("Pacific"). See Note 5.

The Company a development stage company as defined by Statement of Financial Accounting Standard ("SFAS") No.7, *"Accounting and Reporting by Development Stage Enterprises"*. In a development stage company, management devotes most of its activities in evaluating various business opportunities. The ability of the Company to emerge from the development stage is dependent upon its successful efforts in evaluating and acquiring or developing a business opportunity, raising additional equity financing and/or generating significant revenue. There is no guarantee that the Company will be able to raise enough equity to develop and implement a business plan. As at November 30, 2007, the Company has a working capital deficit of \$303,842, has incurred operating losses since inception totalling \$4,051,409 and has not generated any revenues since its inception. Based on the above factors, there is substantial doubt regarding the Company's ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting Policies

(a) Basis of Presentation

These financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States and are expressed in Canadian dollars. The Company's fiscal year-end is February 28.

(b) Interim Financial Statements

These interim unaudited financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

(c) Use of Estimates

The preparation of financial statements in accordance with United States generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of long-lived assets and deferred income tax asset valuations. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(d) Cash and Cash Equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

2. Summary of Significant Accounting Policies (continued)

(e) Property and Equipment

Property and equipment is recorded at cost. Amortization is computed on a declining balance basis at the following rates:

Computer equipment	30%
Furniture and equipment	20%
Leasehold improvements	5 years straight line

(f) Long-lived Assets

In accordance with Financial Accounting Standards Board ("FASB") SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets", the carrying value of intangible assets and other long-lived assets is reviewed on a regular basis for the existence of facts or circumstances that may suggest impairment. The Company recognizes an impairment when the sum of the expected undiscounted future cash flows is less than the carrying amount of the asset. Impairment losses, if any, are measured as the excess of the carrying amount of the asset over its estimated fair value.

(g) Income Taxes

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted SFAS No. 109, "Accounting for Income Taxes", as of its inception. Pursuant to SFAS No. 109 the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in these financial statements because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

(h) Financial Instruments

The carrying values of cash, amounts receivable, accounts payable, accrued liabilities, interest payable, and amounts due from and to related parties approximate their fair values due to the relatively short maturity of these instruments.

(i) Comprehensive Loss

SFAS No. 130, "Reporting Comprehensive Income," establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As at November 30, 2007 and 2006, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

(j) Basic and Diluted Net Income (Loss) per Share

The Company computes net income (loss) per share in accordance with SFAS No. 128, "Earnings per Share" SFAS No. 128 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of common shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period including stock options, using the treasury stock method, and convertible preferred stock, using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential common shares if their effect is anti dilutive.

2. Summary of Significant Accounting Policies (continued)

(k) Stock-based Compensation

Prior to March 1, 2006, the Company accounted for stock based awards under SFAS No. 123, "*Accounting for Stock-Based Compensation*". All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued. Effective March 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123R "*Share Based Payments*", using the modified retrospective transition method. The Company does not currently have a stock option plan. Accordingly, there was no effect on the Company's reported loss from operations, cash flows or loss per share as a result of adopting SFAS No 123R.

Common shares issued to third parties for non-cash consideration are valued based on the fair market value of the services provided or the fair market value of the common stock on the measurement date, whichever is more readily determinable.

(l) Recently Issued Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 160 "Noncontrolling Interests in Consolidated Financial Statements-an amendment of ARB No. 51". SFAS 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the deconsolidation of a subsidiary. The guidance will become effective for the fiscal year beginning after December 15, 2008. The management is in the process of evaluating the impact SFAS 160 will have on the Company's financial statements upon adoption.

In February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial Liabilities – Including an Amendment of FASB Statement No. 115". This statement permits entities to choose to measure many financial instruments and certain other items at fair value. Most of the provisions of SFAS No. 159 apply only to entities that elect the fair value option. However, the amendment to SFAS No. 115 "Accounting for Certain Investments in Debt and Equity Securities" applies to all entities with available-for-sale and trading securities. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provision of SFAS No. 157, "Fair Value Measurements". The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.

In September 2006, the SEC issued Staff Accounting Bulletin ("SAB") No 108, "*Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements*" SAB No. 108 addresses how the effects of prior year uncorrected misstatements should be considered when quantifying misstatements in current year financial statements. SAB No. 108 requires companies to quantify misstatements using a balance sheet and income statement approach and to evaluate whether either approach results in quantifying an error that is material in light of relevant quantitative and qualitative factors. SAB No. 108 is effective for periods ending after November 15, 2006. The adoption of this statement had no material effect on the Company's reported financial position or results of operations.

2. Summary of Significant Accounting Policies (continued)

(a) Recently Issued Accounting Pronouncements (continued)

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements". The objective of SFAS No. 157 is to increase consistency and comparability in fair value measurements and to expand disclosures about fair value measurements. SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 applies under other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. The provisions of SFAS No. 157 are effective for fair value measurements made in fiscal years beginning after November 15, 2007. The adoption of this statement is not expected to have a material effect on the Company's future reported financial position or results of operations.

(k) Recently Adopted Accounting Pronouncements

In June 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes, an interpretation of FASB Statements No. 109" ("FIN 48"). FIN 48 clarifies the accounting for uncertainty in income taxes by prescribing a two-step method of first evaluating whether a tax position has met a more likely than not recognition threshold and second, measuring that tax position to determine the amount of benefit to be recognized in the financial statements. FIN 48 provides guidance on the presentation of such positions within a classified statement of financial position as well as on derecognition, interest and penalties, accounting in interim periods, disclosure, and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. The adoption of this statement did have a material effect on the Company's reported financial position or results of operations.

In March 2006, the FASB issued SFAS No. 156, "Accounting for Servicing of Financial Assets, an amendment of FASB Statement No. 140, Accounting for Transfers and Servicing of Financial Assets and Extinguishments of Liabilities". This statement requires all separately recognized servicing assets and servicing liabilities be initially measured at fair value, if practicable, and permits for subsequent measurement using either fair value measurement with changes in fair value reflected in earnings or the amortization and impairment requirements of Statement No. 140. The subsequent measurement of separately recognized servicing assets and servicing liabilities at fair value eliminates the necessity for entities that manage the risks inherent in servicing assets and servicing liabilities with derivatives to qualify for hedge accounting treatment and eliminates the characterization of declines in fair value as impairments or direct write-downs. SFAS No. 156 is effective for an entity's first fiscal year beginning after September 15, 2006. The adoption of this statement did not have a material effect on the Company's reported financial position or results of operations.

In February 2006, the FASB issued SFAS No. 155, "Accounting for Certain Hybrid Financial Instruments-an amendment of FASB Statements No. 133 and 140", to simplify and make more consistent the accounting for certain financial instruments. SFAS No. 155 amends SFAS No. 133, "Accounting for Derivative Instruments and Hedging Activities", to permit fair value re-measurement for any hybrid financial instrument with an embedded derivative that otherwise would require bifurcation, provided that the whole instrument is accounted for on a fair value basis. SFAS No. 155 amends SFAS No. 140, "Accounting for the Impairment or Disposal of Long-Lived Assets", to allow a qualifying special-purpose entity to hold a derivative financial instrument that pertains to a beneficial interest other than another derivative financial instrument. SFAS No. 155 applies to all financial instruments acquired or issued after the beginning of an entity's first fiscal year that begins after September 15, 2006, with earlier application allowed. The adoption of this statement did not have a material effect on the Company's reported financial position or results of operations.

Bi-Optic Ventures Inc.
(A Development Stage Company)
Notes to the Financial Statements
(expressed in Canadian dollars)
(unaudited)

3. Property and Equipment

	Cost \$	Accumulated Amortization \$	November 30, 2007 Net Carrying Value \$ (unaudited)	February 28, 2007 Net Carrying Value \$
Computer equipment	16,787	7,287	9,500	7,373
Furniture and equipment	6,932	5,893	1,039	1,223
Leasehold improvements	6,157	1,539	4,618	5,542
	29,876	14,719	15,157	14,138

4. Related Party Transactions

- (a) For the nine months ended November 30, 2007, the Company paid or accrued \$22,500 (2006 - \$22,500) in management fees to a company controlled by the CFO of the Company.
- (b) For the nine months ended November 30, 2007, the Company paid or accrued \$22,500 (2006 - \$22,500) in rent to a company controlled by the CFO of the Company.
- (c) For the nine months ended November 30, 2007, the Company paid or accrued \$18,000 (2006 - \$18,000) in professional fees to a company controlled by a director.
- (d) For the nine months ended November 30, 2007, the Company accrued \$3,225 (2006 - \$Nil) in consulting fees to a company controlled by the President of the Company.
- (e) As at November 30, 2007, an amount of \$29,065 (February 28, 2007 - \$Nil) was advanced to Pacific Bio-Pharmaceuticals, Inc. See Note 5.
- (f) As at November 30, 2007, an amount of \$3,582 (February 28, 2007 - \$Nil) was advanced as a prepayment of expenses to a company controlled by two directors of the Company.
- (g) As at November 30, 2007, an amount of \$268 (February 28, 2007 - \$8,186) is owed to the CFO of the Company and is without interest, unsecured and due on demand.
- (h) As at November 30, 2007, an amount of \$9,500 (February 28, 2007 - \$Nil) is owed to the spouse of the CFO of the Company and is without interest, unsecured and due on demand.
- (i) As at November 30, 2007, an amount of \$3,640 (February 28, 2007 - \$Nil) is owed to a company controlled by the President of the Company and is without interest, unsecured and due on demand.
- (j) As at November 30, 2007, an amount of \$111,200 (February 28, 2007 - \$13,000) is owed to companies controlled by the CFO of the Company and is without interest, unsecured and due on demand.
- (k) As at November 30, 2007, an amount of \$2,120 (February 28, 2007 - \$Nil) is owed to a director of the Company and is without interest, unsecured and due on demand.

5. Pending Business Acquisition

On March 22, 2007 the Company entered into an agreement with Pacific, PRB Pharmaceuticals, Inc. ("PRB"), and all of the shareholders of Pacific pursuant to which the Company has agreed to acquire all of the issued and outstanding shares and share purchase warrants of Pacific in exchange for one common share and one share purchase warrant of the Company, as applicable (the "Acquisition"). The Company has agreed to issue a maximum of 20,000,000 common shares and 2,500,000 share purchase warrants to acquire Pacific, assuming the completion of Pacific's planned private placement financing prior to the closing of the Acquisition. Pacific is a privately held Nevada corporation with offices in California that holds rights, directly and through a license from PRB, to certain biopharmaceutical technologies that have demonstrated potential effectiveness against several influenza strains. Provisional patent applications have been made in the United States for certain aspects of the technologies.

The Company has entered into a sponsorship agreement with Global Maxfin Capital Inc. ("Global"). Global has agreed to act as sponsor to the Company in connection with the acquisition of Pacific. Under the terms of the sponsorship agreement, Global will be paid \$15,000 plus reimbursement for its reasonable out-of-pocket expenses and disbursements including legal fees incurred.

The Company will complete a non-brokered private placement of up to 4,000,000 units at a price of \$0.50 per unit for gross proceeds of up to \$2,000,000. Each unit will consist of one common share and one-half transferable share purchase warrant. Each whole purchase warrant will be exercisable into one common share for a period of one year from closing at a price of \$0.65 per share. An additional finder's fee of cash and share purchase warrants, in accordance with Exchange policies, will be paid on a portion of the placement.

Concurrently with the closing, the Company will change its name to "Pacific Bio-Pharmaceuticals International Inc.", or such other name as may be determined by the directors, subject to TSX Venture Exchange (the "Exchange") and shareholder approval. The Company has advanced \$29,065 to Pacific Bio-Pharmaceuticals, Inc. on a demand loan basis without interest. A finder's fee of 500,000 common shares will be payable by the Company on closing of the Acquisition subject to Exchange approval.

6. Loans Payable

The Company received \$200,007; of this amount \$80,000 is due to the spouse of a director. The loan will be repayable upon demand and bear interest at a rate of 1.5% per month. A total of \$7,280 of interest has been accrued at November 30, 2007. The Company will issue 80,000 common shares on completion of the Acquisition in addition to full repayment of the loan plus accrued interest. A cash finders' fee of 7% has been accrued on a portion of the Bridge to an arm's length party. The proceeds of the loan are being used for general working capital purposes and expenses associated with completing the Acquisition.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION OR PLAN OF OPERATIONS

This Quarterly Report on Form 10-QSB contains forward-looking statements, principally in ITEM #2, "Management's Discussion and Analysis of Financial Condition or Plan of Operations". These statements may be identified by the use of words like "plan", "expect", "aim", "believe", "project", "anticipate", "intend", "estimate", "will", "should", "could" and similar expressions in connection with any discussion, expectation, or projection of future operating or financial performance, events or trends. In particular, these include statements about the Company's strategy for growth, property exploration, mineral prices, future performance or results of current or anticipated mineral production, interest rates, foreign exchange rates, and the outcome of contingencies, such as acquisitions and/or legal proceedings.

Forward-looking statements are based on certain assumptions and expectations of future events that are subject to risks and uncertainties. Actual future results and trends may differ materially from historical results or those projected in any such forward-looking statements depending on a variety of factors, including, among other things, the factors discussed in this Quarterly Report under ITEM #3, "Key Information, Risk Factors" and factors described in documents that we may furnish from time to time to the Securities and Exchange Commission. We undertake no obligation to update publicly or revise any forward-looking statements because of new information, future events or otherwise.

Results of Operations

The Company has not had any sources of revenue to date and has financed its activities substantially through equity financing. The Company has incurred net losses each year since inception and, as of 11/30/2007 had an accumulated deficit of (4,051,409).

Effective 11/14/2007, Dr. Linda J. Allison was appointed President & Chief Executive Officer of the Company. Harry Chew stepped down as President/CEO to facilitate the appointment of Dr. Allison. Mr. Chew was appointed to the position of Co-Chairman and continued as Chief Financial Officer. In addition, Dr. Terrance G. Owen, President & Chief Executive Officer of ALDA Pharmaceuticals, was appointed as Co-Chairman of the Company.

On 3/22/2007 the Company entered into an agreement with Pacific Bio-Pharmaceuticals, Inc. ("Pacific"), PRB Pharmaceuticals, Inc. ("PRB"), and all of the shareholders of Pacific pursuant to which the Company has agreed to acquire all of the issued and outstanding shares and share purchase warrants of Pacific in exchange for one common share and one share purchase warrant of the Company, as applicable (the "Acquisition"). The Company has agreed to issue a maximum of 20,000,000 common shares and 2,500,000 share-purchase warrants to acquire Pacific, assuming the completion of Pacific's planned private placement financing prior to the closing of the Acquisition. Pacific is a privately-held Nevada corporation with offices in California that holds rights, directly and through a license from PRB, to certain biopharmaceutical technologies that have demonstrated potential effectiveness against several influenza strains. Provisional patent applications have been made in the United States for certain aspects of the technologies.

The Company has entered into a sponsorship agreement with Global Maxfin Capital Inc. ("Global"). Global has agreed to act as sponsor to the Company in connection with the acquisition of Pacific. Under the terms of the sponsorship agreement, Global will be paid \$15,000 plus reimbursement for its reasonable out-of-pocket expenses and disbursements including legal fees incurred.

The Company plans to complete a non-brokered private placement of up to 4,000,000 units at a price of \$0.50 per unit for gross proceeds of up to \$2,000,000. Each unit would consist of one common share and one-half transferable share purchase warrant. Each whole purchase warrant would be exercisable into one common share for a period of one year from closing at a price of \$0.65 per share. An additional finder's fee of cash and share purchase warrants, in accordance with Exchange policies, would be paid on a portion of the placement.

Concurrently with the closing, the Company anticipates changing its name to "Pacific Bio-Pharmaceuticals International Inc.", or such other name as may be determined by the directors, subject to TSX Venture Exchange and shareholder approval. The Company has advanced \$29,065 to Pacific Bio-Pharmaceuticals, Inc. on a demand loan basis without interest. A finder's fee of 500,000 common shares would be payable by the Company on closing of the Acquisition subject to TSX Venture Exchange approval.

Completion of the Acquisition is subject to a number of conditions, including but not limited to, TSX Venture Exchange acceptance, disinterested shareholder approval, and successful due diligence by all parties. The transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all. **At this time, completion cannot be considered "probable".**

Operating Expenses for the Nine Months Ended 11/30/2007 were \$236,938 [compared to \$275,366 for the same period last year] which included professional fees of \$74,426 (2006 = \$74,594), consulting/management fees of \$73,135 (2006 = \$83,076), office/rent/ telephone of \$52,295 (2006 = \$37,617), and travel/promotion expenses of \$19,635 (2006 = \$61,449). The reported decrease was related to the current pending status of a potential acquisition versus last year's extensive search for, the negotiations with, and due diligence on potential acquisitions. Net Loss for the Nine Months was (\$236,938) vs. (\$275,366). Loss Per Share was (\$0.02) vs (\$0.03).

Liquidity and Capital Resources

The Company had a working capital deficit of (\$303,832) at 11/30/2007, compared to a working capital deficit of (\$60,429) at 2/28/2007. Cash Used by Operating Activities was (\$174,658), including the (\$236,938) Net Loss; \$58,846 net changes in operating assets/liabilities was the significant adjustment; much of this was the \$105,542 in "due to related parties" regarding advances and loans made to the Company, and the (\$32,647) advances to various related parties in connection with due diligence and sponsorship expenses with respect to the Company's proposed acquisition of Pacific Bio-Pharmaceuticals, Inc. Net Cash Used by Investing Activities was (\$9,909). Net Cash Provided by Financing Activities and Net Cash Used in Investing Activities was \$200,007 in proceeds from loans payable.

ITEM 3. CONTROLS AND PROCEDURES

At the end of third fiscal quarter ended 11/30/2007 (the "Evaluation Date"), under the supervision and with the participation of the Company's management, including its Chief Executive Officer and its Chief Financial Officer, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures (as defined in Rule 13a-15e under the Exchange Act). Based upon that evaluation, the Company's management, including the Chief Executive Officer and the Chief Financial Officer, concluded that, as of the Evaluation Date, concluded that the Company's disclosure controls and procedures were effective to ensure that information the Company is required to disclose in the reports that it files or submits with the Securities and Exchange Commission under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Commission's rules and forms, and to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company's management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

The Company's management, including the Chief Executive Officer and the Chief Financial Officer, identified no change in the Company's internal control over financial reporting that occurred during the Company's Fiscal Quarter Ended November 30, 2007 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

ITEM 3A(T). CONTROLS AND PROCEDURES

Not Applicable

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

No Disclosure Necessary.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

- a. No Disclosure Necessary.
- b. No Disclosure Necessary.
- c. No Disclosure Necessary.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

No Disclosure Necessary.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No Disclosure Necessary.

ITEM 5. OTHER INFORMATION

- a. Reports on Form 8-K:
 - 1. Form 8-K filed 11/15/2007 regarding 11/14/2007 Press Release discussing FD Disclosure regarding "the appointment of Dr. Linda J. Allison as President & CEO of the Company".
- b. Information required by Item 401(g) of Regulation S-B:
No Disclosure Necessary.

ITEM 6. EXHIBITS

Exhibit 31.1

Certification required by Rule 13a-14(a) or Rule 15d-14(a)

Exhibit 32.1

Certification Required by Rule 13a-14(b) or Rule 15d-14(b) and section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Bi-Optic Ventures Inc. -- SEC File No. 0-49685
Registrant

Date: January 14, 2008

/s/ Dr. Linda J. Allison
Dr. Linda J. Allison, President/CEO/Director

Exhibit 31.1
CERTIFICATIONS

I, Dr. Linda J. Allison, certify that:

- (1) I have reviewed this Form 10-QSB of Bi-Optic Ventures, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
- (4) I am responsible for establishing and maintaining disclosure controls and procedures [as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)] and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
- (5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information;
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: January 14, 2008

/s/ Dr. Linda J. Allison

Dr. Linda J. Allison, President and Chief Executive Officer

Exhibit 31.2
CERTIFICATIONS

I, Harry Chew, certify that:

- (1) I have reviewed this Form 10-QSB of Bi-Optic Ventures, Inc.;
- (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- (3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;
- (4) I am responsible for establishing and maintaining disclosure controls and procedures [as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)] and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have:
 - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - (c) Evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - (d) Disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and
- (5) I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):
 - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information;
 - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: January 14, 2008

/s/ Harry Chew

Harry Chew, Co-Chairman and Chief Financial Officer

**EXHIBIT 32.1
CERTIFICATIONS**

**CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002**

I, Dr. Linda J. Allison, President and Chief Executive Officer of Bi-Optic Ventures, Inc. (the "Company") do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. This Quarterly Report on Form 10-QSB of the Company for the period ended November 30, 2007 as filed with the Securities and Exchange Commission (the "report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 14, 2008

/s/ Dr. Linda J. Allison

Dr. Linda J. Allison, President and Chief Executive Officer

EXHIBIT 32.2
CERTIFICATIONS

CERTIFICATION PURSUANT TO THE SARBANES-OXLEY ACT
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

I, Harry Chew, Co-Chairman and Chief Financial Officer of Bi-Optic Ventures, Inc. (the "Company") do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. This Quarterly Report on Form 10-QSB of the Company for the period ended November 30, 2007 as filed with the Securities and Exchange Commission (the "report"), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: January 14, 2008

/s/ Harry Chew
Harry Chew, Co-Chairman and Chief Financial Officer